Hanmi Pharm "US Partner Spectrum Sued for Patent Infringement Related to Rolontis"

Bioverativ Files Patent Infringement Lawsuit in US Court
Claims Damages and Seeks Injunction

[Asia Economy Reporter Kim Ji-hee] Hanmi Pharmaceutical announced on the 4th that Bioverativ has filed a patent infringement lawsuit against Spectrum regarding the neutropenia treatment biopharmaceutical 'Rolontis.'

Spectrum is a partner company that signed a license agreement for Rolontis with Hanmi Pharmaceutical in 2012. It currently holds the global development and sales rights for Rolontis, excluding Korea, China, and Japan. The license agreement also includes a general clause that exempts Spectrum from patent infringement lawsuits filed by third parties.

Bioverativ filed a patent infringement lawsuit in the Delaware court in the United States on the 28th of last month, requesting damages and a preliminary injunction.

In response, Spectrum stated, "The production, use, and commercialization activities of Rolontis do not infringe on any patents," and added, "We will strongly respond to protect the development and commercialization rights of Rolontis according to the terms of the contract with Hanmi Pharmaceutical."

Hanmi Pharmaceutical also indicated a strong response. A Hanmi Pharmaceutical official said, "We believe Bioverativ filed the patent lawsuit because Rolontis' FDA approval is imminent," and emphasized, "Hanmi and Spectrum have already recognized this company's actions and have been preparing thoroughly for a long time."

He continued, "Since the core technology of Rolontis, Lapscovery, is a proprietary technology developed independently by Hanmi, we will respond together with Spectrum to protect the rights of Rolontis."

This content was produced with the assistance of AI translation services.